Encore Global Management LP Acquires Shares of 6,000 iShares Biotechnology ETF $IBB

Posted by Jessica Moore on Jul 29th, 2026

Encore Global Management LP bought a new stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,000 shares of the financial services provider’s stock, valued at approximately $1,013,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Basepoint Wealth LLC bought a new position in shares of iShares Biotechnology ETF in the 4th quarter worth $26,000. Cary Street Partners Financial LLC bought a new stake in shares of iShares Biotechnology ETF during the 4th quarter worth $29,000. Darwin Wealth Management LLC purchased a new position in iShares Biotechnology ETF in the second quarter worth $25,000. Caitlin John LLC purchased a new position in iShares Biotechnology ETF in the fourth quarter worth $34,000. Finally, Cornerstone Planning Group LLC bought a new position in iShares Biotechnology ETF in the fourth quarter valued at $35,000. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Price Performance

Shares of NASDAQ IBB opened at $190.52 on Wednesday. The stock’s 50-day moving average is $180.54 and its 200 day moving average is $174.32. iShares Biotechnology ETF has a 1-year low of $130.25 and a 1-year high of $199.05.

iShares Biotechnology ETF Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 18th. Shareholders of record on Monday, June 15th were given a dividend of $0.0238 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $0.10 dividend on an annualized basis and a yield of 0.0%.

iShares Biotechnology ETF Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.